Kris Rothleutner

Kris Rothleutner has a rich and diverse work experience. Kris is currently the Head of US ALS Marketing at Amylyx Pharmaceuticals since 2021. Prior to this, they served as the Sr. Director, Global Brand Lead for Cerebral ALD at bluebird bio from 2017 to 2021. In 2016, Kris worked as the Director of Life Cycle Management (Orphan) at Horizon Pharma plc. Before that, they owned their own marketing company, 708 Marketing, from 2014 to 2015.

Kris also had an extensive tenure at Takeda Pharmaceuticals, where they held various roles. From 2012 to 2014, they were the Director of Global Marketing for New Products and played a crucial role in the commercial program of fasiglifam, a novel oral treatment for type 2 diabetes. Prior to this, they served as the Senior Product Manager for Diabetes Marketing from 2009 to 2012 and as the Product Manager for US Diabetes Marketing in 2009-2010. Kris also gained experience as an Associate Manager in New Product Planning and as a Sales Representative during their time at Takeda Pharmaceuticals. Kris began their career at Takeda as a Sr. Financial Analyst in Sales and Marketing from 2001 to 2003.

Before joining Takeda Pharmaceuticals, Kris worked as a Manager of Operational Analysis at Universal Access from 2000 to 2001. Kris started their career with Abbott Laboratories, where they held various positions, including Financial Analyst from 1999 to 2000 and a part of their Financial Professional Development Program from 1997 to 1999.

Overall, Kris Rothleutner's professional journey showcases their expertise and leadership in pharmaceutical marketing and brand management roles across various companies.

Kris Rothleutner obtained a Bachelor of Science degree in Accounting from DePaul University from 1993 to 1997. Subsequently, they pursued a Master of Business Administration degree in Marketing and Strategy from Northwestern University - Kellogg School of Management from 2001 to 2005.